References
Drug Enforcement Administration, Department of Justice (2005) Schedules of controlled substances: placement of pregabalin into schedule V. Fed Regist 70(144):43633–43635
European Medicines Agency (EMA). Lyrica – Procedural steps taken after authorisation. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/human/000546/WC500046604.pdf. Accessed 26th August 2010.
Schwan S, Sundström A, Stjernberg E, Hallberg E, Hallberg P (2010) A signal for abuse potential for pregabalin – results from the Swedish spontaneous adverse reaction reporting system. Eur J Clin Pharmacol 66:947–953
Caster O, Kindlundh-Högberg A, Hopstadius J, Norén GN (2010) Early indicators of drug dependence. Pharmacoepidem Dr S 19(S1):S224–S225
Conflicts of interest
The findings presented in this letter were enabled by the results of a methodologically oriented project aimed at identifying drug dependence indicators on individual case safety reports. This methodological project, in turn, received funding by the EU-FP7 project MONITORING MEDICINES (grant number 223566). The funding source had no involvement in any parts of the production of this letter.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Caster, O., Edwards, I.R., Norén, G.N. et al. Earlier discovery of pregabalin’s dependence potential might have been possible. Eur J Clin Pharmacol 67, 319–320 (2011). https://doi.org/10.1007/s00228-010-0920-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-010-0920-4